SCHEMBL4501026

SCHEMBL4501026

CCOC(=O)c1ccc(NC(=O)Nc2ccc(CC3CCN(C4C5CC6CC4CC(O)(C6)C5)C3=O)c(Cl)c2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 2/20 0.48
TRPV1 Q8NER1 2/20 0.41
GAA P10253 4/20 0.39
ALDH1A1 P00352 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
MAPT P10636 7/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
LMNA P02545 2/20 0.39
CASP3 P42574 1/20 0.39
SENP7 Q9BQF6 1/20 0.39
MAPK1 P28482 3/20 0.39
USP2 O75604 1/20 0.39
RAB9A P51151 1/20 0.38
EPHX2 P34913 3/20 0.38
ABL1 P00519 1/20 0.38
HTT P42858 1/20 0.38
RIN1 Q13671 1/20 0.38
TP53 P04637 1/20 0.37
HPGD P15428 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4515700 0.89 HSD11B1 (0.54) HSD11B1GAAEPHX2HTTTP53
SCHEMBL5547540 0.89 HSD11B1 (0.51) HSD11B1SMN1; SMN2RAB9AEPHX2
SCHEMBL4517112 0.87 HSD11B1 (0.50) HSD11B1EPHX2
SCHEMBL4514117 0.86 HSD11B1 (0.54) HSD11B1EPHX2
SCHEMBL4517664 0.86 HSD11B1 (0.51) HSD11B1EPHX2
SCHEMBL4508493 0.85 HSD11B1 (0.48) HSD11B1MAPTLMNAEPHX2TP53
SCHEMBL4501204 0.85 HSD11B1 (0.56) HSD11B1ALDH1A1EPHX2
SCHEMBL4511346 0.84 HSD11B1 (0.51) HSD11B1GAASMN1; SMN2MAPTMEN1
SCHEMBL4518194 0.83 HSD11B1 (0.54) HSD11B1MEN1KMT2ARAB9AEPHX2
SCHEMBL4514645 0.82 TRPV1 (0.44) TRPV1GAAALDH1A1SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
EP-1864971-A1 PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES Takeda Pharmaceutical Company Limited (JP) 2007-12-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes HSD11B1, HSD17B1, HSD11B2 HSD11B1 1/4885TRPV1 3739/4885GAA 1261/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.